Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
in vivo
Biotech
Gene editor shelves sole clinical asset, lays off 25% of staff
Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine.
Gabrielle Masson
May 19, 2025 2:28pm
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
May 7, 2025 10:00am
Novartis taps Vyriad’s viral vectors for in vivo T cell editing
Nov 20, 2024 12:00pm
PharmaLegacy snaps up preclinical CRO
Sep 16, 2024 3:50pm
Sanofi, Scribe seal new in vivo collab worth more than $1.2B
Jul 17, 2023 11:30am
George Church-founded biotech tacks on $40M series A
Jul 14, 2022 8:00am
